The commission will develop a framework for scientists, clinicians, and regulatory authorities on the appropriate use of human germline genome editing.
To solve the problem, the researchers developed new variants of the editors that still edit DNA efficiently but have significantly lower RNA editing activity.
This webinar will discuss a study that used CRISPR/Cas9 to engineer mice harboring risk variants associated with glaucoma in order to assess their functional relevance.
